AbCellera Biologics Inc.
ABCL
$4.05
-$0.13-3.11%
| Weiss Ratings | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D | |||
| Rating Factors | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.99 | |||
| Price History | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.36% | |||
| 30-Day Total Return | -14.06% | |||
| 60-Day Total Return | -16.38% | |||
| 90-Day Total Return | -6.47% | |||
| Year to Date Total Return | -24.26% | |||
| 1-Year Total Return | -42.82% | |||
| 2-Year Total Return | -51.83% | |||
| 3-Year Total Return | -84.64% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -46.09% | |||
| 52-Week Low % Change | 12.14% | |||
| Price | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $8.05 | |||
| 52-Week Low Price | $3.87 | |||
| 52-Week Low Price (Date) | Oct 30, 2023 | |||
| 52-Week High Price (Date) | Jul 19, 2023 | |||
| Valuation | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.27B | |||
| Enterprise Value | 587.47M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.52 | |||
| Earnings Per Share Growth | -205.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 33.16 | |||
| Price/Book (Q) | 1.10 | |||
| Enterprise Value/Revenue (TTM) | 15.45 | |||
| Price | $4.34 | |||
| Enterprise Value/EBITDA (TTM) | -2.76 | |||
| Enterprise Value/EBIT | -2.48 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 290.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604-559-9005 | |||
| Address | 2215 Yukon Street Vancouver, BC V5Y 0A1 | |||
| Website | www.abcellera.com | |||
| Country | Canada | |||
| Year Founded | 2012 | |||
| Profitability | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -623.79% | |||
| Profit Margin | -384.99% | |||
| Management Effectiveness | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -9.79% | |||
| Return on Equity | -- | |||
| Income Statement | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 38.03M | |||
| Total Revenue (TTM) | 38.03M | |||
| Revenue Per Share | $0.13 | |||
| Gross Profit (TTM) | 6.24M | |||
| EBITDA (TTM) | -212.81M | |||
| EBIT (TTM) | -237.21M | |||
| Net Income (TTM) | -146.40M | |||
| Net Income Avl. to Common (TTM) | -146.40M | |||
| Total Revenue Growth (Q YOY) | -57.40% | |||
| Earnings Growth (Q YOY) | -57.73% | |||
| EPS Diluted (TTM) | -0.52 | |||
| EPS Diluted Growth (Q YOY) | -62.64% | |||
| Balance Sheet | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 760.59M | |||
| Cash Per Share (Q) | $2.62 | |||
| Total Current Assets (Q) | 871.99M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.15B | |||
| Current Ratio (Q) | 7.327 | |||
| Book Value Per Share (Q) | $3.96 | |||
| Total Assets (Q) | 1.49B | |||
| Total Current Liabilities (Q) | 119.01M | |||
| Total Debt (Q) | 77.38M | |||
| Total Liabilities (Q) | 335.78M | |||
| Total Common Equity (Q) | 1.15B | |||
| Cash Flow | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -221.11M | |||
| Cash from Financing (TTM) | 10.36M | |||
| Net Change in Cash (TTM) | -254.04M | |||
| Levered Free Cash Flow (TTM) | -102.96M | |||
| Cash from Operations (TTM) | -43.88M | |||
